MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Gemcitabine hydrochloride
CAS No. : 122111-03-9
MCE 国际站：Gemcitabine hydrochloride
产品活性：Gemcitabine Hydrochloride (LY 188011 Hydrochloride) 是一种嘧啶核苷类似物抗代谢药 (nucleoside antimetabolite/analog) 和抗肿瘤剂。Gemcitabine 抑制 DNA 合成 (DNA synthesis) 和修复，导致细胞自噬 (autophagy) 和凋亡 (apoptosis)。
研究领域：Cell Cycle/DNA Damage | Autophagy | Apoptosis
作用靶点：DNA/RNA Synthesis | Nucleoside Antimetabolite/Analog | Autophagy | Apoptosis
In Vitro: Gemcitabine Hydrochloride (purchased from MedChem Express, 0.003-1 μM; 3 days) kills both mouse and human senescent cells effectively and potently.
Gemcitabine Hydrochloride inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively.
In Vivo: Gemcitabine Hydrochloride can be administered via endotracheal spray in rats without marked toxicity with a maximum tolerated dose of 4 mg/kg once a week for 9 weeks. The toxicity of Gemcitabine is lower via lung than oral administration at dosages of 2, 4, and 6 mg/kg.
Treatment of the LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mice with either Gemcitabine (50 mg/kg, i.p.) or the combination DMAPT/Gemcitabine Hydrochloride significantly increases the median survival time by more than 30 days compared to the placebo group (254.5 or 255 days vs. 217.5 days, respectively).
相关产品：Covalent Screening Library Plus | Natural Product-like Compound Library | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Apoptosis Compound Library | Cell Cycle/DNA Damage Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Antiviral Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Reprogramming Compound Library | Nucleotide Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | FDA Approved & Pharmacopeial Drug Library | Anti-Lung Cancer Compound Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Rare Diseases Drug Library | Children’s Drug Library | Chemotherapy Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Heterocyclic Compound Library | Off-patent Drug Library | Cell Death Library | Anti-Hematopathy Compound Library | Radiosensitizer Library | Bioactive Compound Library Max | MG-132 | Cycloheximide | Doxorubicin hydrochloride | Bafilomycin A1 | Tamoxifen | Y-27632 | Paclitaxel | Z-VAD-FMK | LY294002 | 2-Deoxy-D-glucose | Angiotensin II human | Acetylcysteine | Staurosporine | Actinomycin D | SB-431542 | 5-Fluorouracil | Bortezomib | Oxaliplatin | Deferoxamine mesylate | Sorafenib | Trametinib | Gemcitabine | Temozolomide | Etoposide | Rotenone | Mdivi-1 | Monomethyl auristatin E | Decitabine | Ruxolitinib | Elesclomol
热门产品线：重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。
